Bilateral panuveitis associated with letrozole therapy.
Publication/Presentation Date
6-23-2026
Abstract
PURPOSE: Letrozole is a non-steroidal aromatase inhibitor commonly used for the treatment of postmenopausal estrogen receptor-positive breast cancer. We report a novel case of bilateral panuveitis associated with letrozole therapy.
METHODS: Retrospective chart review.
RESULTS: A 39-year-old female with a history of breast cancer presented with bilateral anterior chamber and vitreous inflammation, perivenular sheathing, retinal hemorrhages, and a focal area of retinal whitening in the left eye six weeks after starting letrozole therapy. Extensive infectious and systemic inflammatory work-up was negative. With letrozole cessation and corticosteroid therapy, the inflammation resolved, and the visual acuity improved to 20/20 bilaterally.
DISCUSSION AND CONCLUSION: Letrozole-associated panuveitis has not previously been reported. This case highlights the importance of detailed medication history as well as the need for interdisciplinary collaboration when managing drug-induced uveitis. Early recognition and appropriate therapy can result in favorable visual outcomes.
ISSN
1937-1578
Published In/Presented At
Cheng, B. T., Muste, J. C., Zafar, S., Djulbegovic, M. B., Kim, E. D., Beca, F. A., Dunn, J. P., Garg, S. J., & Deaner, J. D. (2026). Bilateral panuveitis associated with letrozole therapy. Retinal cases & brief reports, 10.1097/ICB.0000000000001952. Advance online publication. https://doi.org/10.1097/ICB.0000000000001952
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
42328833
Department(s)
Administration and Leadership
Document Type
Article